| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Molecular Pharmacology and 2 Medicine, Albert Einstein College of Medicine and 3 Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, New York
Requests for reprints: Hayley McDaid, Department of Molecular Pharmacology, Albert Einstein College of Medicine, Golding 201, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-2192; Fax: 718-430-8959; E-mail: mcdaid{at}aecom.yu.edu.
Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cytoprotective pathway in human cancer cell lines and tumors. We have previously shown additivity between Taxol and the MEK inhibitor, U0126 in human cancer cell lines. Here, the combination of Taxol with an orally bioavailable MEK inhibitor, CI-1040, was evaluated in human lung tumors heterotransplanted into nude mice. Unlike xenograft models that are derived from cells with multiple genetic alterations due to prolonged passage, heterotransplanted tumor models are more clinically relevant. Combined treatment with both drugs resulted in inhibition of tumor growth in all models and tumor regressions in three of four models tested, supporting our previous observation that Taxol's efficacy is potentiated by MEK inhibition. Concurrent administration was superior to intermittent dosing. Pharmacodynamic assessments of tumors indicated that suppression of MEK was associated with induction of S473 phosphorylated Akt and reduced proliferation in the combination groups relative to single agents, in addition to suppression of fibroblast growth factor–mediated angiogenesis and reduced expression of vascular endothelial growth factor. These findings are significant and indicate that this combination may have broad therapeutic applications in a diverse range of lung tumors with different intrinsic chemosensitivities.
Key Words: Taxol • CI-1040 • Combination treatment • Heterotransplanted tumor models • Non–Small Cell Lung Cancer (NSCLC)
This article has been cited by other articles:
|
|
 |
|
  C. Wasylyk, H. Zheng, C. Castell, L. Debussche, M.-C. Multon, and B. Wasylyk Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules Cancer Res., March 1, 2008; 68(5): 1275 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hamed, W. Hawkins, C. Mitchell, D. Gilfor, G. Zhang, X.-Y. Pei, Y. Dai, M. P. Hagan, J. D. Roberts, A. Yacoub, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo Mol. Cancer Ther., March 1, 2008; 7(3): 616 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Friday and A. A. Adjei Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy Clin. Cancer Res., January 15, 2008; 14(2): 342 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Haass, K. Sproesser, T. K. Nguyen, R. Contractor, C. A. Medina, K. L. Nathanson, M. Herlyn, and K. S.M. Smalley The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel Clin. Cancer Res., January 1, 2008; 14(1): 230 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Legrier, C.-P. H. Yang, H.-G. Yan, L. Lopez-Barcons, S. M. Keller, R. Perez-Soler, S. B. Horwitz, and H. M. McDaid Targeting Protein Translation in Human Non Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression Cancer Res., December 1, 2007; 67(23): 11300 - 11308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Mhaidat, R. F. Thorne, X. D. Zhang, and P. Hersey Regulation of Docetaxel-Induced Apoptosis of Human Melanoma Cells by Different Isoforms of Protein Kinase C Mol. Cancer Res., October 1, 2007; 5(10): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Davies, A. Logie, J. S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P. D. Smith AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol. Cancer Ther., August 1, 2007; 6(8): 2209 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ji, Z. Wang, S. A. Perera, D. Li, M.-C. Liang, S. Zaghlul, K. McNamara, L. Chen, M. Albert, Y. Sun, et al. Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models Cancer Res., May 15, 2007; 67(10): 4933 - 4939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Mhaidat, X. D. Zhang, C. C. Jiang, and P. Hersey Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH2-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1/2 Pathway Clin. Cancer Res., February 15, 2007; 13(4): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Chin and R. Herbst Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol. Cancer Ther., October 1, 2006; 5(10): 2580 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Davis Profile of Susan Band Horwitz PNAS, July 5, 2006; 103(27): 10163 - 10165. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
